Active Biotech Completes First Safety Cohort in Tasquinimod MF Study

The first three-patient safety cohort completed a six-week evaluation under the amended HOVON 172 MF protocol. One SAE/DLT resolved, and all patients remain on study; enrollment continues with three more patients to confirm safety and set the Phase II dose.